Latest Hotspot

Innate Pharma's Preclinical Success with IPH45: A Nectin-4 Targeted ADC Unveiled at AACR 2024

12 April 2024
3 min read

Innate Pharma SA has disclosed the initial findings from preclinical research on IPH45, an innovative exatecan-linked Antibody Drug Conjugate (ADC) with a focus on Nectin-4. This data reveal was part of a spoken address at the 2024 American Association for Cancer Research (AACR) Annual Meeting.

👇Unlock in-depth information about this drug - its R&D Status, Core Patent, Clinical Trials, and Global Approval Status. Click on the image below and explore the latest data immediately.

图形用户界面, 文本, 应用程序, 电子邮件

描述已自动生成

During early-stage scientific assessments, evidence has shown that the compound IPH45 successfully blocks the growth of Nectin-4 positive cancer cells in both lab dish settings and live animal experiments. This includes models not responding to Enfortumab Vedotin. Notably, IPH45 outperforms EV in a range of patient-derived xenograft (PDX) models for urothelial cancer, functioning effectively in contexts with both high and low Nectin-4 expression. Moreover, when combined with anti-PD1 therapy in animal studies, IPH45 enhances the suppression of tumor progression, while maintaining an acceptable tolerability profile in toxicological evaluations conducted on animals.

”IPH45 represents a distinct and innovative Nectin-4 targeting Antibody Drug Conjugate, showcasing promising effectiveness in preclinical tumor models with different Nectin-4 expression profiles. Its utilization of the exatecan payload presents heightened effectiveness for impacting surrounding cells and extends the treatment window when compared to ADCs conjugated with MMAE,” noted Prof. Eric Vivier, DVM, PhD, the Chief Scientific Officer at Innate Pharma.

He further emphasized the compound's capability to shape future treatments for patients diagnosed with various Nectin-4 reliant cancers, even extending beyond those with elevated Nectin-4 like bladder cancer. Given these positive outcomes, the thrust to propel IPH45 into clinical development phases is strong.

Nectin-4, which is an adhesive protein located on cell surfaces, is typically overexpressed in an array of solid malignancies such as those affecting the urothelial, breast, lung, ovarian, and pancreas tissues, with minimal presence in normal healthy tissues. IPH45, a new exatecan-conjugated Antibody Drug Conjugate, zeroes in on Nectin-4. Lasting well in animal models, IPH45 reveals its potential to attack tumors both outside and inside the body’s living systems. Currently, IPH45 is advancing toward its initial trial involving human participants.

👇Explore the most recent advancements in drug research, indications, organizations, clinical trials, results, and patents related to this target by clicking the image link below. Dive in to gain deeper insights!

图形用户界面, 文本, 应用程序

描述已自动生成

According to the data provided by the Synapse Database, As of April 11, 2024, there are 42 investigational drugs for the Nectin-4 target, including 28 indications, 46 R&D institutions involved, with related clinical trials reaching 77, and as many as 2348 patents.

IPH-45 is an antibody drug conjugate and fusion protein that targets nectin-4, a protein associated with neoplasms. It is being developed by Innate Pharma SA for the treatment of neoplasms. Currently in the preclinical phase, IPH-45 is undergoing testing to determine its safety and efficacy before progressing to clinical trials.

图形用户界面, 文本, 应用程序

描述已自动生成

Synthekine's STK-012 Shows Promise in Treating Advanced Solid Cancers
Latest Hotspot
3 min read
Synthekine's STK-012 Shows Promise in Treating Advanced Solid Cancers
12 April 2024
Synthekine Unveils Encouraging Early Outcomes from Early-stage Clinical Study of Altered IL-2 Agent, STK-012, Aimed at Advanced Solid Cancer Therapy.
Read →
Initial Human Trials of OBX-115 Show Promise at 25-Week Milestone
Latest Hotspot
3 min read
Initial Human Trials of OBX-115 Show Promise at 25-Week Milestone
12 April 2024
Obsidian Therapeutics Reveals Encouraging Safety and Effectiveness Results After 25 Weeks of Monitoring in Initial Human Trials for OBX-115.
Read →
Initial Trial of CytomX's CX-2051, a Targeted ADC for Solid Tumors
Latest Hotspot
3 min read
Initial Trial of CytomX's CX-2051, a Targeted ADC for Solid Tumors
12 April 2024
CytomX Therapeutics has revealed initial treatment using CX-2051, a selective EpCAM-targeted antibody-drug conjugate, in an early-stage trial involving individuals with progressive solid malignancies.
Read →
Pharma Frontiers: Daily Digest of Global Pharmaceutical News - April 12
Pharma Frontiers
10 min read
Pharma Frontiers: Daily Digest of Global Pharmaceutical News - April 12
12 April 2024
April 12th latest updates in the global new drug development field, including progress in new drug research and development, transaction information, and partnership developments.
Read →
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.